COVID-19 vaccination experience in patients with rheumatoid arthritis treated at a single VA medical center.
COVID-19 vaccination experience in patients with rheumatoid arthritis treated at a single VA medical center.
复制标题
DOI：
10.1016/j.jvacx.2023.100295
复制
发表时间：
2023-08
期刊：
影响因子：
3.8
通讯作者：
Mattar, Maya
中科院分区：
文献类型：
--
作者：
Doumeth, Sarah Abi;Gong, Jenny;Silversteyn, Laura;O'Mara, Megan;Singh, Shivali;Anthony, Donald;Mattar, Maya
在引入新冠肺炎疫苗后，对于接种新冠肺炎疫苗是否会导致免疫系统过度激活，进而导致自身免疫性疾病发作，一直存在不确定性。这项研究的目的是评估接受新冠肺炎基因疫苗的类风湿关节炎(RA)患者是否有更高的疾病复发风险。我们在2021年12月至2022年2月在路易斯托克斯克利夫兰退伍军人医学中心进行了一项单中心回顾和前瞻性研究。我们包括100名积极接受免疫抑制治疗的类风湿性关节炎(RA)患者，并接受了三剂辉瑞-BioNTech疫苗。调查问卷被用来收集关于他们的RA的数据，以及他们在接种疫苗后是否出现症状。我们的主要目的是确定新冠肺炎疫苗接种后类风湿关节炎红斑的发生率。次要终点是估计疫苗的副作用概况，并检查患者在接种疫苗后是否感染新冠肺炎。在接种3剂疫苗后的两个月内，没有患者报告出现类风湿性关节炎发作的症状。最常见的疫苗副作用是注射部位疼痛(n=14)、头痛(n=11)、疲劳(n=7)和肌痛(n=4)。5名患者在接种疫苗前感染新冠肺炎，8名患者在接种疫苗后5个月内感染新冠肺炎，8名患者中3名在第二次接种后5个月内感染，8名患者中5名在第三次接种后3个月内感染。接种新冠肺炎辉瑞基因疫苗的RA患者似乎不会在接种疫苗后出现主要症状、红斑或副作用。需要对更多的类风湿性关节炎和其他自身免疫性疾病患者进行进一步研究，以更好地了解新冠肺炎疫苗的安全性和有效性。
Following the introduction of the COVID-19 vaccines, there has been uncertainty as to whether receiving the COVID-19 vaccine will result in overactivation of the immune system and subsequently lead to an autoimmune disease flare. The purpose of this study was to assess whether rheumatoid arthritis (RA) patients who received the mRNA COVID-19 vaccine are at increased risk for disease flare. We conducted a single-center retrospective and prospective study at the Louis Stokes Cleveland VA Medical Center between 12/2021 and 2/2022. We included 100 patients with rheumatoid arthritis (RA) who were actively on immunosuppressive therapy and received three doses of the Pfizer-BioNTech vaccine. A survey questionnaire was used to collect data about their RA and if they developed symptoms post vaccination. Our primary end point was to determine incidence of flare of RA after COVID-19 vaccine. Secondary end points were to estimate the side effect profile from the vaccine, and to check if patients developed a COVID-19 infection after they received the vaccine. None of the patients reported symptoms of RA flare within two months of receiving the 3 doses of the vaccine. Most common vaccine side effects were soreness over the injection site (n = 14), headache (n = 11), fatigue(n = 7) and myalgias(n = 4). 5 patients developed a COVID-19 infection prior to receiving the vaccine, 8 after being vaccinated, 3 of the 8 within 5 months from the second dose and 5 out of the 8 within 3 months from the third vaccine dose. RA patients receiving the COVID-19 Pfizer mRNA vaccine do not appear to commonly develop major symptoms, flares or side effects following the vaccine. Further research with larger numbers of patients with rheumatoid arthritis as well as those with other autoimmune disease is needed to better understand the safety and effectiveness of COVID-19 vaccine.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
--
作者：
Pinte L;Negoi F;Ionescu GD;Caraiola S;Balaban DV;Badea C;Mazilu D;Dumitrescu B;Mateescu B;Ionescu R;Parvu MI;Baicus C
通讯作者：
Baicus C
影响因子：
39
作者：
Sun, Jing;Zheng, Qulu;Patel, Rena C.
通讯作者：
Patel, Rena C.
影响因子：
27.4
作者：
Machado, Pedro M.;Lawson-Tovey, Saskia;Mariette, Xavier
通讯作者：
Mariette, Xavier
香港类风湿关节炎患者中的两剂共证于19号疫苗接种和可能的关节炎炎症。
影响因子：
27.4
作者：
Li X;Tong X;Yeung WWY;Kuan P;Yum SHH;Chui CSL;Lai FTT;Wan EYF;Wong CKH;Chan EWY;Lau CS;Wong ICK
通讯作者：
Wong ICK